Use of ketone esters for prevention of CNS oxygen toxicity
The present invention demonstrates the therapeutic use of ketone esters for seizure disorders, Alzheimer's disease and malignant brain cancer, which are associated with metabolic dysregulation. The administration of ketone esters resulted therapeutic ketosis and neuroprotection against seizures resulting from CNS oxygen toxicity. Supplemental ketones were also found to reduce superoxide production in cultured cortex neurons exposed to hyperbaric oxygen and Aβ-42, and to decrease proliferation and viability in U87 glioma cells. These observations support the therapeutic effect of ketones for seizure disorders, Alzheimer's disease and malignant brain cancer. The ketone esters may be derived from acetoacetate and can include R,S-1,3-butanediol acetoacetate monoester, R,S-1,3-butanediol acetoacetate diester, or a combination of the two.
1. A method of increasing latency time and resistance to hyperoxia-induced seizure due to hyperbaric oxygen (HBO 2 ) exposure comprising inducing mild ketosis in a subject in need of hyperbaric oxygen by administering a therapeutically effective dose of a composition comprising R,S-1,3-butanediol acetoacetate and R,S-1,3- butanediol acetoacetate diester in a sufficient amount to elevate blood β-hydroxybutyrate (BHB) and acetoacetate (AcAc) ketones and pO 2 levels and maintain the elevated level for about four (4) hours wherein BHB and AcAc ketones are elevated in the blood to a total amount of at least 1 mM,
wherein the composition is administered at least 30 minutes prior to hyperbaric oxygen exposure,
wherein administration of the composition does not increase pCO 2 in blood, and reduces superoxide anion production and thus oxidative stress, and
wherein the composition is administered with an unrestricted diet.
2. A method of protecting against hyperoxia-induced oxidative stress comprising inducing mild ketosis in a subject in need of hyperbaric oxygen by administering a therapeutically effective dose of a ketone ester derived from acetoacetate in a sufficient amount to elevate blood β-hydroxybutyrate (BHB) and acetoacetate (AcAc) ketones and pO 2 levels in blood and maintain the elevated levels for about four (4) hours wherein BHB and AcAc ketones are elevated in the blood to a total amount of at least 1 mM, wherein administration of the ketone ester derived from acetoacetate does not increase pCO 2 in blood, and reduces superoxide anion production and thus the hyperoxia-induced oxidative stress in the subject,
wherein the ketone ester derived from acetoacetate is administered at least 30 minutes prior to hyperbaric oxygen exposure, and
wherein the ketone ester is administered with an unrestricted diet.
3. The method of claim 2 , wherein the ketone ester is a R,S-1,3-butanediol acetoacetate ester.
4. The method of claim 3 , wherein the ketone ester is R,S-1,3-butanediol acetoacetate monoester.
5. The method of claim 3 , wherein the ketone ester is R,S-1,3-butanediol acetoacetate diester.
6. The method of claim 3 , wherein the ketone ester is a combination of R,S-1,3-butanediol acetoacetate monoester and R,S-1,3-butanediol acetoacetate diester.
7. A method of protecting against central nervous system oxygen toxicity in a subject in need of hyperbaric oxygen comprising:
administering a therapeutically effective dose of a ketone ester derived from acetoacetate in a sufficient amount to elevate blood β-hydroxybutyrate (BHB) and acetoacetate (AcAc) ketones and pO 2 levels in blood and maintain the elevated levels for four (4) hours or more wherein BHB and AcAc ketones are elevated in the blood to a total amount of at least 1 mM, wherein administration of the ketone ester derived from acetoacetate does not increase pCO2 in blood, and reduces superoxide anion production and hyperoxia- induced oxidative stress in the subject,
wherein the ketone ester derived from acetoacetate is administered at least 30 minutes prior to hyperbaric oxygen exposure, and
wherein the ketone ester is administered with an unrestricted diet.
8. The method of claim 7 , wherein the ketone ester is a R,S-1,3-butanediol acetoacetate ester.
9. The method of claim 8 , wherein the ketone ester is selected from the group consisting ofR,S-1,3-butanediol acetoacetate monoester; R,S- 1 , 3 -butanediol acetoacetate diester; and combinations thereof.
10. The method of claim 1 , wherein the blood ketone level is elevated to greater than 1 mM within 30 minutes.
11. The method of claim 1 , wherein the blood pO 2 level is elevated to about 30% within 30 minutes.